Zilebesiran REVERSIR Overview

Under Investigation: Reversal Technology

Disease State(s) Under Investigation	Hypertension[1]
MoA	Designed to counteract siRNA-mediated pharmacodynamic effects[1]
Route of Administration	Subcutaneous[2]

Clinical Trials Overview

Phase 1	Treatment Arms	Primary Endpoint
Completed Sept 2025 ☑		
Safety, Tolerability, and PK of Single Ascending Doses of **ALN-AGT01 RVR** Healthy Volunteers[2]	ALN-AGT01 RVR; placebo	Safety (frequency of AEs up to 3 months)

Phase 2	Treatment Arms	Primary Endpoint
Recruiting ⏳		
Efficacy, PD, and Safety of **ALN-AGT01 RVR** in adults with mild to moderate hypertension pretreated with zilebesiran Adults with mild to moderate hypertension pretreated with zilebesiran[3]	ALN-AGT01 RVR; placebo	Percentage recovery from baseline in serum AGT up to Day 4 (Part A) and in mean seated office SBP at Day 4 and Day 7 (Part B)

The safety and efficacy of Zilebesiran + REVERSIR has not been established by any health authority.

AE, adverse event; AGT, angiotensinogen; MoA, mechanism of action; PD, pharmacodynamics; PK, pharmacokinetics; RVR, REVERSIR, siRNA, small interfering ribonucleic acid . *1. Ye D et al. Hypertension 2024;81(7):1491–9. 2. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT06675565 (Accessed March 5, 2026). 3. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07553442 (Accessed July 30, 2026).*

Alnylam